File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin

TitlePrognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin
Authors
KeywordsCoronary artery disease
Statin intolerance
High sensitive troponin level
Issue Date2019
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccardiovascdisord/
Citation
BMC Cardiovascular Disorders, 2019, v. 19 n. 1, p. article no. 168 How to Cite?
AbstractBackground: The prognostic implication of statin in tolerance (SI) in those with stable CAD remains unclear. We hypothesized that SI is of higher prognostic significance in stable CAD patients with elevated high-sensitive cardiac troponin I (hs-cTnI). Methods: A total of 952 stable CAD patients from the prospective Hong Kong CAD study who had complete clinical data, biomarker measurements and who were prescribed statin therapy were studied. Results: We identified 13 (1.4%) and 125 (13.1%) patients with complete and partial SI, respectively. At baseline, patients with SI were more likely to have diabetes mellitus and a higher hs-cTnI level, but no difference in LDL-C level compared with those without SI. After 51 months of follow-up, patients with SI had a higher mean LDL-C level than those without SI. A total of 148 (15.5%) patients developed major adverse cardiovascular events (MACEs). Both SI (HR 1.52, 95% CI 1.06–2.19, P = 0.02) and elevated hs-cTnI (HR 3.18, 95% CI 2.07–4.89, P < 0.01) were independent predictors of a MACE in patients with stable CAD. When stratified by hs-cTnI level, SI independently predicted MACE-free survival only in those with elevated hs-cTnI (HR 1.51, 95% CI 1.01–2.24, P = 0.04). Conclusions: SI independently predicted MACE in patients with stable CAD and high hs-cTnI, but not in those with low hs-cTnI. Hs-cTnI may be used to stratify stable CAD patients who have SI for intensive lipid-lowering therapy using non-statin agents.
Persistent Identifierhttp://hdl.handle.net/10722/284982
ISSN
2020 Impact Factor: 2.298
2015 SCImago Journal Rankings: 1.023
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHai, JJ-
dc.contributor.authorWong, YK-
dc.contributor.authorWong, CK-
dc.contributor.authorUn, KC-
dc.contributor.authorChan, PH-
dc.contributor.authorSiu, CW-
dc.contributor.authorYiu, KH-
dc.contributor.authorLau, CP-
dc.contributor.authorTse, HF-
dc.date.accessioned2020-08-07T09:05:11Z-
dc.date.available2020-08-07T09:05:11Z-
dc.date.issued2019-
dc.identifier.citationBMC Cardiovascular Disorders, 2019, v. 19 n. 1, p. article no. 168-
dc.identifier.issn1471-2261-
dc.identifier.urihttp://hdl.handle.net/10722/284982-
dc.description.abstractBackground: The prognostic implication of statin in tolerance (SI) in those with stable CAD remains unclear. We hypothesized that SI is of higher prognostic significance in stable CAD patients with elevated high-sensitive cardiac troponin I (hs-cTnI). Methods: A total of 952 stable CAD patients from the prospective Hong Kong CAD study who had complete clinical data, biomarker measurements and who were prescribed statin therapy were studied. Results: We identified 13 (1.4%) and 125 (13.1%) patients with complete and partial SI, respectively. At baseline, patients with SI were more likely to have diabetes mellitus and a higher hs-cTnI level, but no difference in LDL-C level compared with those without SI. After 51 months of follow-up, patients with SI had a higher mean LDL-C level than those without SI. A total of 148 (15.5%) patients developed major adverse cardiovascular events (MACEs). Both SI (HR 1.52, 95% CI 1.06–2.19, P = 0.02) and elevated hs-cTnI (HR 3.18, 95% CI 2.07–4.89, P < 0.01) were independent predictors of a MACE in patients with stable CAD. When stratified by hs-cTnI level, SI independently predicted MACE-free survival only in those with elevated hs-cTnI (HR 1.51, 95% CI 1.01–2.24, P = 0.04). Conclusions: SI independently predicted MACE in patients with stable CAD and high hs-cTnI, but not in those with low hs-cTnI. Hs-cTnI may be used to stratify stable CAD patients who have SI for intensive lipid-lowering therapy using non-statin agents.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccardiovascdisord/-
dc.relation.ispartofBMC Cardiovascular Disorders-
dc.rightsBMC Cardiovascular Disorders. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCoronary artery disease-
dc.subjectStatin intolerance-
dc.subjectHigh sensitive troponin level-
dc.titlePrognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin-
dc.typeArticle-
dc.identifier.emailHai, JJ: haishjj@hku.hk-
dc.identifier.emailWong, YK: debbieyk@hku.hk-
dc.identifier.emailChan, PH: phmchan@hku.hk-
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailYiu, KH: khkyiu@hku.hk-
dc.identifier.emailLau, CP: cplau@hkucc.hku.hk-
dc.identifier.emailTse, HF: hftse@hkucc.hku.hk-
dc.identifier.authorityHai, JJ=rp02047-
dc.identifier.authorityChan, PH=rp01864-
dc.identifier.authoritySiu, CW=rp00534-
dc.identifier.authorityYiu, KH=rp01490-
dc.identifier.authorityTse, HF=rp00428-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12872-019-1152-x-
dc.identifier.pmid31307391-
dc.identifier.pmcidPMC6633694-
dc.identifier.scopuseid_2-s2.0-85069459696-
dc.identifier.hkuros311670-
dc.identifier.volume19-
dc.identifier.issue1-
dc.identifier.spagearticle no. 168-
dc.identifier.epagearticle no. 168-
dc.identifier.isiWOS:000475707000001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1471-2261-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats